Dr Lori Laffel is Chief of the Pediatric, Adolescent and Young Adult Section; Senior Investigator/Head of the Section on Clinical, Behavioral and Outcomes Research; and Professor of Pediatrics at the Joslin Diabetes Center, Harvard Medical School. She has published over 300 articles in peer-reviewed journals. She has been on the Advisory Board of the International Society of Pediatric and Adolescent Diabetes (ISPAD) and a member of the Clinical and Research Advisory Committees for JDRF. Dr. Laffel is involved with the American Diabetes Association (ADA), as a member of the Boston Leadership Board, past member of the National Board of Directors, Committee for Professional Practice Guidelines, co-chair on the Working Group on Transition, and past chair of ADA’s Youth Strategies Committee. She is a member of ADA’s Pathway Mentor Advisory Program. Dr. Laffel is a global editor for the journal Diabetic Medicine. Her research focuses on understanding and overcoming challenges to diabetes self-management in order to improve glycemic control and other biomedical and psychosocial outcomes. Her research also aims to evaluate new diabetes technologies and optimize their use across the life span, including continuous glucose monitors (CGM) and automated insulin delivery systems. She is recipient of many NIH and foundation-funded grants. She received ADA’s 2015 Outstanding Physician-Clinician Award, the Greater Boston Chamber of Commerce 2016 Pinnacle Award, and the 2016 University of Miami School of Medicine Hall-of-Fame Award.

Dr. Rayhan Lal has lived with type 1 diabetes for several decades and studied electrical engineering and computer science at U.C. Berkeley. During his work in engineering his two younger sisters developed T1D and he decided to become an adult and pediatric endocrinologist. As an engineer and physician-scientist with diabetes, his primary research interest is the design, development and testing of new diabetes technology with his mentor, Dr. Bruce Buckingham. Rayhan collaborates with members of the Stanford Diabetes Research Center, industry, and open-source diabetes community to bypass the biological, technological, and human factor limitations of existing devices.

Luigi Laviola, M.D., Ph.D. University of Bari “Aldo Moro”, Bari, Italy Luigi Laviola is Full Professor of Endocrinology, at the University of Bari “Aldo Moro”, Bari, Italy. He is the Director of the Postgraduate Program in Endocrinology and Metabolism, University of Bari “Aldo Moro” School of Medicine. He received his M.D. degree from the University of Bari Aldo Moro and his Ph.D. degree from the University of Naples Federico II, in Italy. After completing clinical and research training in Endocrinology and Metabolism at the University of Naples, Italy, he worked for several years at the Joslin Diabetes Center and Harvard Medical School in Boston, MA, USA. He has received distinguished scientific awards from various international and national institutions, including the Juvenile Diabetes Research Foundation International (JDRF) Fellowship (New York, NY, USA), the Mary K. Iacocca Foundation Fellowship (Boston, MA, USA), and the Italian Society of Diabetology. He has served as a member of multiple Steering Committees of the Italian Society of Diabetology (“Scientific Committee”, “Diabetic Nephropathy Study Group”, “Diabetes, Hypertension and Kidney Study Group”) and of the Scientific Committee of the Italian Society of Endocrinology. He has been member (2012-2019) and chair (2015-2019) of the Steering Committee of the “Technology & Diabetes” Intersociety Study Group. He is President of the Puglia Regional Section of the Italian Society of Diabetology (2014-present). He is member of the National Steering Committee of the Italian Society of Diabetology (2020-present). Luigi Laviola’s scientific interests include the molecular mechanisms of insulin and IGF action, the molecular determinants of insulin resistance, the biochemical and molecular basis of cardiovascular complications in diabetes mellitus, the pathophysiology of adipose tissue, clinical applications of diabetes therapy and advanced technologies in diabetes therapy. Luigi Laviola has published >100 papers in international scientific journals, with an H-Index of 36 and 4449 citations (Scopus).

Julia Lawton in Professor of Health and Social Science at the Usher Institute, University of Edinburgh. She leads an internationally recognized programme of qualitative research exploring the perspectives and experiences of people living with type 1 and type 2 diabetes and their health care providers. She has undertaking extensive research exploring use of new diabetes technologies, including closed-loop systems.

General Manager at PKvitality: 25 years of experience as sales & marketing director, managing 30+ teams and building business from 0 to 150M€, ex CMO of Withings, LaCie, Alcatel Mobile phones, startup and large group experience. In charge of Sales, Marketing, Funding, Product experience, at PKvitality. Specialities: technology marketing, product & services, monetization, UX, design, communication, web advertising, sales B2C/B2B, innovation management, and change management.

Dr Leelarathna is a Consultant Diabetologist / Senior Lecturer at Manchester Diabetes Centre / University of Manchester since May 2014 and co-lead Type 1 diabetes and transition services. His areas of expertise include insulin pump therapy, continuous and flash glucose monitoring, artificial pancreas systems (closed-loop insulin delivery) and hypoglycaemia. Dr Leelarathna completed higher specialist training in London UK, and Masters in Diabetes and Endocrinology from Kings College, London in 2009 followed by PhD from University of Cambridge in 2014. His areas of expertise include insulin pump therapy, continuous and flash glucose monitoring, artificial pancreas systems (closed-loop insulin delivery) and hypoglycaemia. He is currently chief / principal investigator for several type 1 diabetes technology studies. He has over 80 peer-reviewed publications in leading diabetes and general medical journals.

Over 20 years experience in the chronic disease management of diabetes and cardiovascular disease. Clinical Management and Medical Affairs roles in diabetes pharmaceutical and medical device industry. Over 15 years experience in building, growing and leading an international commercial clinical and/or medical science teams at Dexcom, Inc. Currently leading strategic domestic and international medical science, education and communication initiatives for continuous glucose monitoring and managing a team of Medical Science Liaisons focusing on medical education & communications, evidence strategy and real world evidence and strategic KOL development. Continue to maintain clinical credentials as a Registered Dietitian and Certified Diabetes Care & Education Specialist. Masters Degree in Nutrition & Health Education. National and international speaker and subject matter expert on diabetes technology and application of continuous glucose management in clinical practice.

Shmuel Levit is Head of the Endocrinology and Diabetology Institute at Assuta Medical Centers. He is a leading specialist-endocrinologist and an expert in the treatment of diabetes. In the past - founder and director of a number of medical centers around Israel, such as institutions for the treatment of diabetes mellitus in Petah Tikva and Hadera, and a diabetes treatment center for the Meuhedet Health Fund in Samaria. As a leading specialist in the field of diabetes mellitus, Dr. Levit actively promotes the introduction of novel methods of diagnostics and treatment, including the use of glucose sensors and insulin pumps. He engages in serious scientific work and teaches specialized courses on the treatment of diabetes for physicians in Israel and abroad. He is also an active participant of multiple professional conferences, meetings, journal clubs, and so on, and has conducted numerous clinical presentations and discussions. Author of breakthrough concepts of pathogenesis and therapy of Type 1 and Type 2 Diabetes. His revolutionary approach to induction of remission in Type 1 diabetes has recently been patented.

After building her own automated insulin delivery system, Dana Lewis helped found the open source artificial pancreas movement (known as “OpenAPS”), making safe and effective automated insulin delivery technology available (sooner) for people with diabetes around the world. She authored the book, "Automated Insulin Delivery: How artificial pancreas “closed loop” systems can aid you in living with diabetes", to help more people understand automated insulin delivery systems, in addition to a series of children's books such as "Understanding Automated Insulin Delivery: A basic book for kids, family, and friends of people living with diabetes". She is currently researching numerous diabetes-related data science and open source AID projects.

Dr. Andreas Liebl, MD Medical Director Center for Diabetes and Metabolism at the Fachklinik Bad Heilbrunn, Germany Andreas Liebl is Medical Director of the Center for Diabetes and Metabolism at the Fachklinik in Bad Heilbrunn, Germany. His research interests include insulin therapy, pharmacoeconomics, insulin pump therapy, intraperitoneal insulin therapy, and continuous glucose monitoring (CGM) and other diabetes technology. He is an advisor for the German Health Authorities and Payers Organisations. Dr Liebl has been a board member of ‘Diabetes Technology – Insulin Pumps and Blood Glucose Sensors’, which is a working group of the German Diabetes Association (DDG). He is also Past-Chairman of the Diabetes Expert Commission FKDB within the DDG. Dr Liebl has been author or co-author of more than 100 national and international publications, and has delivered numerous presentations at scientific meetings all over the world.